| Lei, Feng |
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response |
|
|
| Recruiting | 3 | 593 | RoW | PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine | Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 02/27 | 02/30 | | |
NPC-GTV, NCT04384627: Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy |
|
|
| Active, not recruiting | 3 | 445 | RoW | Delineating the GTV according to the pretreatment or post-IC tumor extension | Sun Yat-sen University, First People's Hospital of Foshan, Cancer Research Institute of Zhongshan City | Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy | 10/24 | 10/26 | | |
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. |
|
|
| Recruiting | 3 | 580 | RoW | QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy | Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd. | Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | 12/28 | 12/30 | | |
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 418 | RoW | Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Akeso Pharmaceuticals, Inc. | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 01/25 | 01/27 | | |
NCT04453813: Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 226 | RoW | Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment | 07/25 | 07/27 | | |
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 454 | RoW | IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy) | Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province | Nasopharyngeal Carcinoma | 09/26 | 09/29 | | |
NCT04448522: Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 508 | RoW | reduced dosage IMRT, conventional dosage IMRT | Sun Yat-sen University, National Cancer Centre, Singapore, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital | Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy | 08/26 | 08/28 | | |
NCT04453826: Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 388 | RoW | Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy | 09/26 | 09/28 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations |
|
|
| Recruiting | N/A | 170 | RoW | Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Arteriovenous Malformations | 10/25 | 10/26 | | |
NCT03353467: Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | N/A | 228 | RoW | Endoscopic surgery, Intensity-modulated radiotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, People's Hospital of Guangxi | Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer | 10/25 | 10/28 | | |
| Li, Xian-Ming |
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 418 | RoW | Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Akeso Pharmaceuticals, Inc. | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 01/25 | 01/27 | | |
| Yang, Kaibin |
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response |
|
|
| Recruiting | 3 | 593 | RoW | PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine | Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 02/27 | 02/30 | | |
